The treatment of endometrial cancer (EC) is challenging. There is no standard of care for patients who progressed after carboplatin and paclitaxel (CT) and all available drugs show a small response and poor long-term survival in this scenario. The objective of this study was to evaluate the efficacy and toxicity profile of palliative doxorubicin after progression to CT therapy in advanced or recurrent EC. A retrospective review of the Brazilian National Cancer Institute database between 2009 and 2013 was performed, and all patients with recurrent and advanced EC treated with palliative doxorubicin after progression on CT were included. Progression-free survival (PFS), overall survival (OS), objective response rates as well as toxicity were evaluated. A total of 33 patients were enrolled, with a median age of 65.7 years. Objective responses were documented in 12.1% (3.0% of complete responses and 9.1% of partial responses). The median PFS was 4.4 months, and the median OS was 8.1 months for patients exposed to doxorubicin. The most common adverse event was anemia observed in 60.6% of patients. This retrospective study suggests that doxorubicin has a modest activity in patients with advanced or recurrent EC after treatment with CT.

No abstract

Laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) is used to compare the suitability of four cassiterite (SnO 2 ) materials (SPG, Yankee, AY-4 and Jian-1), and three matrix-mismatched reference materials (NIST SRM 612, NIST SRM 614 and 91500 zircon) for normalisation of U-Pb and Pb-Pb isotope ratios in cassiterite. The excess variance of ages determined by LA-ICP-MS is estimated to be AE0.33% for 207 Pb/ 206 Pb vs. 208 Pb/ 206 Pb isochron ages and AE 1.8% and for U-Pb ages. Incorporation of this excess variance in cassiterite ages is necessary for realistic uncertainties. 207 Pb-206 Pb ages are advantageous for dating Precambrian cassiterite such as SPG compared with U-Pb ages as matrix effect on instrumental mass fractionation of Pb isotopes are generally considered to be minor. We note minor bias in 207 Pb/ 206 Pb vs. 208 Pb/ 206 Pb isochron ages (~0.6%) when using either the NIST SRM 614 or 91500 zircon reference materials and emphasise the requirement for uncertainty propagation of all sources of error and reference materials with comparable U and Pb mass fraction to the cassiterite. The 238 U/ 206 Pb isotopic ratios from normalisation to matrix-mismatched reference materials show varied results, which emphasises the need to use matrix-matched reference materials for calculating U-Pb ages. When cross-calibrated against each other, LA-ICP-MS U-Pb ages of the ca. 1535 Ma SPG, ca. 245 Ma Yankee and ca. 155 Ma Jian-1 cassiterites are all consistent with their ID-TIMS values.